Serum high-molecular-weight adiponectin as a marker for the evaluation and care of subjects with metabolic syndrome and related disorders

Journal of Atherosclerosis and Thrombosis

Volumn 17, Issue 12, 2010, Pages 1201-1211

  Hirose, Hiroshi ^a,b   Yamamoto, Yukihiro ^b   Seino Yoshihara, Yoshie ^b   Kawabe, Hiroshi ^a,b   Saito, Ikuo ^a,b  

^a KEIO UNIVERSITY   (Japan)

^b KEIO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

And diabetes mellitus; High molecular weight adiponectin; Insulin resistance; Metabolic syndrome

Indexed keywords

ADIPONECTIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HIGH MOLECULAR WEIGHT ADIPONECTIN; UNCLASSIFIED DRUG;

CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; DISEASE COURSE; GENETIC ASSOCIATION; HUMAN; METABOLIC SYNDROME X; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PREDICTION; PROTEIN BLOOD LEVEL; REVIEW;

EID: 78650833211     PISSN: 13403478     EISSN: 18803873     Source Type: Journal    
DOI: 10.5551/jat.6106     Document Type: Review

References (60)

1. Matsuzawa Y, Funahashi T, and Nakamura T: Molecular mechanism of metabolic syndrome X: contribution of ad-ipocytokines adipocyte-derived bioactive substances. Ann NY Acad Sci, 1999; 892: 146-154
2. Reaven GM: Banting lecture 1988. Role of insulin resistance in human disease. Diabetes, 1988; 37: 1595-1607
3. Kaplan NM: The deadly quartet. Upper-body obesity, glucose intolerance, hypertriglyceridemia, and hypertension. Arch Intern Med, 1989; 149: 1514-1520
4. DeFronzo RA and Ferrannini E: Insulin resistance. A multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia, and atherosclerotic cardiovascular disease. Diabetes Care, 1991; 14: 173-194
5. Nakamura T, Tsubono Y, Kameda-Takemura K, Funa-hashi T, Yamashita S, Hisamichi S, Kita T, Yamamura T, and Matsuzawa Y: Magnitude of sustained multiple risk factors for ischemic heart disease in Japanese employees: a case-control study. Jpn Circ J, 2001; 65: 11-17
6. Maeda K, Okubo K, Shimomura I, Funahashi T, Matsu-zawa Y, and Matsubara K: cDNA cloning and expression of a novel adipose specific collagen-like factor, apM1 (AdiPose Most abundant Gene transcript 1). Biochem Bio-phys Res Commun, 1996; 221: 286-289
7. Nakano Y, Tobe T, Choi MN, Mazda T, and Tomita M: Isolation and characterization of GBP28, a novel gelatin-binding protein purified from human plasma. J Biochem (Tokyo), 1996; 120: 803-812
8. Yamauchi T, Kamon J, Waki H, Terauchi Y, Kubota N, Hara K, Mori Y, Ide T, Murakami K, Tsuboyama-Kasaoka N, Ezaki O, Akanuma Y, Gavrilova O, Vinson C, Reit-man ML, Kagechika H, Shudo K, Yoda M, Nakano Y, Tobe K, Nagai R, Kimura S, Tomita M, Froguel P, and Kadowaki T: The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity. Nat Med, 2001; 7: 941-946
9. Berg AH, Combs T P, Du X, Brownlee M, and Scherer PE: The adipocyte-secreted protein Acrp30 enhances hepatic insulin action. Nat Med, 2001; 7: 947-953
10. Hotta K, Funahashi T, Bodkin NL, Ortmeyer HK, Arita Y, Hansen BC, and Matsuzawa Y: Circulating concentrations of the adipocyte protein adiponectin are decreased in parallel with reduced insulin sensitivity during the progression to type 2 diabetes in rhesus monkeys. Diabetes, 2001; 50: 1126-1133
11. Kubota N, Terauchi Y, Yamauchi T, Kubota T, Moroi M, Matsui J, Eto K, Yamashita T, Kamon J, Satoh H, Yano W, Froguel P, Nagai R, Kimura S, Kadowaki T, and Noda T: Disruption of adiponectin causes insulin resistance and neointimal formation. J Biol Chem, 2002; 277: 25863-25866
12. Maeda N, Shimomura I, Kishida K, Nishizawa H, Matsu-da M, Nagaretani H, Furuyama N, Kondo H, Takahashi M, Arita Y, Komuro R, Ouchi N, Kihara S, Tochino Y, Okutomi K, Horie M, Takeda S, Aoyama T, Funahashi T, and Matsuzawa Y: Diet-induced insulin resistance in mice lacking adiponectin/ACRP30. Nat Med, 2002; 8: 731-737
13. Kamada Y, Tamura S, Kiso S, Matsumoto H, Saji Y, Yo-shida Y, Fukui K, Maeda N, Nishizawa H, Nagaretani H, Okamoto Y, Kihara S, Miyagawa J, Shinomura Y, Funa-hashi T, and Matsuzawa Y: Enhanced carbon tetrachlo-ride-induced liver fibrosis in mice lacking adiponectin. Gastroenterology, 2003; 125: 1796-1807
14. Bråkenhielm E, Veitonmäki N, Cao R, Kihara S, Matsu-zawa Y, Zhivotovsky B, Funahashi T, and Cao Y: Adipo-nectin-induced antiangiogenesis and antitumor activity involve caspase-mediated endothelial cell apoptosis. Proc Natl Acad Sci USA, 2004; 101: 2476-2481
15. Otabe S, Yuan X, Fukutani T, Wada N, Hashinaga T, Na-kayama H, Hirota N, Kojima M, and Yamada K: Overex-pression of human adiponectin in transgenic mice results in suppression of fat accumulation and prevention of premature death by high-calorie diet. Am J Physiol Endocri-nol Metab, 2007; 293: E210-E218
16. Kobayashi H, Ouchi N, Kihara S, Walsh K, Kumada M, Abe Y, Funahashi T, and Matsuzawa Y: Selective suppression of endothelial cell apoptosis by the high molecular weight form of adiponectin. Circ Res, 2004; 94: e27-e31
17. Pajvani UB, Hawkins M, Combs T P, Rajala MW, Doeb-ber T, Berger J P, Wagner JA, Wu M, Knopps A, Xiang AH, Utzschneider KM, Kahn SE, Olefsky JM, Buchanan TA, and Scherer PE: Complex distribution, not absolute amount of adiponectin, correlates with thiazolidinedione-mediated improvement in insulin sensitivity. J Biol Chem, 2004; 279: 12152-12162
18. Ouchi N, Kobayashi H, Kihara S, Kumada M, Sato K, Inoue T, Funahashi T, and Walsh K: Adiponectin stimu lates angiogenesis by promoting cross-talk between AMP- activated protein kinase and Akt signaling in endothelial cells. J Biol Chem, 2004; 279: 1304-1309
19. Wang Y, Lam KS, Xu JY, Lu G, Xu LY, Cooper GJ, and Xu A: Adiponectin inhibits cell proliferation by interacting with several growth factors in an oligomerization-de-pendent manner. J Biol Chem, 2005; 280: 18341-18347
20. Aso Y, Yamamoto R, Wakabayashi S, Uchida T, Takay-anagi K, Takebayashi K, Okuno T, Inoue T, Node K, Tobe T, Inukai T, and Nakano Y: Comparison of serum high-molecular-weight (HMW) adiponectin with total adipo-nectin concentrations in type 2 diabetic patients with coronary artery disease using a novel enzyme-linked immu-nosorbent assay to detect HMW adiponectin. Diabetes, 2006; 55: 1954-1960
21. Waki H, Yamauchi T, Kamon J, Ito Y, Uchida S, Kita S, Hara K, Hada Y, Vasseur F, Froguel P, Kimura S, Nagai R, and Kadowaki T: Impaired multimerization of human ad-iponectin mutants associated with diabetes: Molecular structure and multimer formation of adiponectin. J Biol Chem, 2003; 278: 40352-40363
22. Hara K, Horikoshi M, Yamauchi T, Yago H, Miyazaki O, Ebinuma H, Imai Y, Nagai R, and Kadowaki T: Measurement of the high-molecular weight form of adiponectin in plasma is useful for the prediction of insulin resistance and metabolic syndrome. Diabetes Care, 2006; 29: 1357-1362
23. Seino Y, Hirose H, Saito I, and Itoh H: High molecular weight multimer form of adiponectin as a useful marker to evaluate insulin resistance and metabolic syndrome in Japanese men. Metabolism, 2007; 56: 1493-1499
24. Nakashima R, Kamei N, Yamane K, Nakanishi S, Na-kashima A, and Kohno N: Decreased total and high molecular weight adiponectin are independent risk factors for the development of type 2 diabetes in Japanese-Americans. J Clin Endocrinol Metab, 2006; 91: 3873-3877
25. Inoue T, Kotooka N, Morooka T, Komoda H, Uchida T, Aso Y, Inukai T, Okuno T, and Node K: High molecular weight adiponectin as a predictor of long-term clinical outcome in patients with coronary artery disease. Am J Cardiol, 2007; 100: 569-574
26. Arita Y, Kihara S, Ouchi N, Takahashi M, Maeda K, Mi-yagawa J, Hotta K, Shimomura I, Nakamura T, Miyaoka K, Kuriyama H, Nishida M, Yamashita S, Okubo K, Mat-subara K, Muraguchi M, Ohmoto Y, Funahashi T, and Matsuzawa Y: Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. Biochem Biophys Res Commun, 1999; 257: 79-83
27. Hotta K, Funahashi T, Arita Y, Takahashi M, Matsuda M, Okamoto Y, Iwahashi H, Kuriyama H, Ouchi N, Maeda K, Nishida M, Kihara S, Sakai N, Nakajima T, Hasegawa K, Muraguchi M, Ohmoto Y, Nakamura T, Yamashita S, Hanafusa T, and Matsuzawa Y: Plasma concentrations of a novel, adipose-specific protein, adiponectin, in type 2 diabetic patients. Arterioscler Thromb Vase Biol, 2000; 20: 1595-1599
28. Weyer C, Funahashi T, Tanaka S, Hotta K, Matsuzawa Y, Pratley RE, and Tataranni PA: Hypoadiponectinemia in obesity and type 2 diabetes: close association with insulin resistance and hyperinsulinemia. J Clin Endocrinol Metab, 2001; 86: 1930-1935
29. Yamamoto Y, Hirose H, Saito I, Tomita M, Taniyama M, Matsubara K, Okazaki Y, Ishii T, Nishikai K, and Saruta T: Correlation of adipocyte-derived protein, adiponectin with insulin resistance index and serum HDL-cholesterol, independent of body mass index in the Japanese population. Clin Sci, 2002; 103: 137-142
30. Hirose H, Kawai T, Yamamoto Y, Taniyama M, Tomita M, Matsubara K, Okazaki Y, Ishii T, Oguma Y, Takei I, and Saruta T Effects of pioglitazone on metabolic parameters, body fat distribution, and serum adiponectin levels in Japanese male patients with type 2 diabetes. Metabolism, 2002; 51: 314-317
31. Yamamoto Y, Hirose H, Saito I, Nishikai K, and Saruta T Adiponectin, an adipocyte-derived protein, predicts future insulin resistance: two-year follow-up study in Japanese population. J Clin Endocrinol Metab, 2004: 89: 87-90
32. Yamamoto Y, Hirose H, Miyashita K, Nishikai K, Saito I, Taniyama M, Tomita M, and Saruta T: PPARy2 gene Prol2Ala polymorphism may influence serum level of an adipocyte-derived protein, adiponectin, in the Japanese population. Metabolism, 2002; 51: 1407-1409
33. Nakano Y, Tajima S, Yoshimi A, Akiyama H, Tsushima M, Tanioka T, Negoro T, Tomita M, and Tobe T: A novel en-zyme-linked immunosorbent assay specific for high-molecular-weight adiponectin. J Lipid Res, 2006; 47: 1572-1582
34. Daimon M, Oizumi T, Saitoh T, Kameda W, Hirata A, Yamaguchi H, Ohnuma H, Igarashi M, Tominaga M, and Kato T: Decreased serum levels of adiponectin are a risk factor for the progression to type 2 diabetes in the Japanese population: the Funagata study. Diabetes Care, 2003; 26: 2015-2020
35. Pischon T, Girman CJ, Hotamisligil GS, Rifai N, Hu FB, and Rimm EB: Plasma adiponectin levels and risk of myocardial infarction in men. JAMA, 2004; 291: 1730-1737
36. Seino Y, Hirose H, Saito I, and Itoh H: High molecular weight adiponectin is a predictor of progression to metabolic syndrome: a population-based 6-year follow-up study in Japanese men. Metabolism, 2009; 58: 355-360
37. Kappert K, Tsuprykov O, Kaufmann J, Fritzsche J, Ott I, Goebel M, Bähr IN, Hässle PL, Gust R, Fleck E, Unger T, Stawowy P, and Kintscher U: Chronic treatment with losartan results in sufficient serum levels of the metabolite EXP3179 for PPARgamma activation. Hypertension, 2009; 54: 738-743
38. Uchida T, Shimizu M, Sakai Y, Nakano T, Hara K, Take-bayashi K, Inoue T, Node K, Inukai T, Takayanagi K, and Aso Y: Effects of losartan on serum total and high-molecular weight adiponectin concentrations in hypertensive patients with metabolic syndrome. Metabolism, 2008; 57: 1278-1285
39. Nishimura H, Sanaka T, Tanihata Y, Naito T, Higuchi C, and Otsuka K: Losartan elevates the serum high-molecular weight-adiponectin isoform and concurrently improves insulin sensitivity in patients with impaired glucose metabolism. Hypertens Res, 2008; 31: 1611-1618
40. Watanabe S, Okura T, Kurata M, Irita J, Manabe S, Miy-oshi K, Fukuoka T, Murakami K, and Higaki J: The effect of losartan and amlodipine on serum adiponectin in Japanese adults with essential hypertension. Clin Ther, 2006; 28: 1677-1685
41. Aksnes TA, Seljeflot I, Torjesen PA, Höieggen A, Moan A, and Kjeldsen SE: Improved insulin sensitivity by the an-giotensin II-receptor blocker losartan is not explained by adipokines, inflammatory markers, or whole blood viscosity. Metabolism, 2007; 56: 1470-1477
42. Guo LL, Pan Y, and Jin HM: Adiponectin is positively associated with insulin resistance in subjects with type 2 diabetic nephropathy and effects of angiotensin II type 1 receptor blocker losartan. Nephrol Dial Transplant, 2009; 24: 1876-1883
43. Piecha G, Adamczak M, Chudek J, and Wiecek A: Indap-amide decreases plasma adiponectin concentration in patients with essential hypertension. Kidney Blood Press Res, 2007; 30: 187-194
44. Zappe DH, Sowers JR, Hsueh WA, Haffner SM, Deed-wania PC, Fonseca VA, Keeling L, and Sica DA: Metabolic and antihypertensive effects of combined angiotensin receptor blocker and diuretic therapy in prediabetic hypertensive patients with the cardiometabolic syndrome. J Clin Hypertens, 2008; 10: 894-903
45. Huang SS, Wu TC, Lin SJ, and Chen JW: Combination of an ACE inhibitor and indapamide improves blood pressure control, but attenuates the beneficial effects of ACE inhibition on plasma adiponectin in patients with essential hypertension. Circ J, 2009; 73: 2282-2287
46. Hirose H, Kawabe H, and Saito I: Effects of losartan/ hydrochlorothiazide treatment, after change from ARB at usual dosage, on blood pressure and various metabolic parameters including high-molecular weight adiponectin in Japanese male hypertensive subjects. Clin Exp Hypertens, 2010; in press
47. Schupp M, Janke J, Clasen R, Unger T, and Kntscher U: Angiotensin type 1 receptor blockers induce peroxisome proliferator-activated receptor-gamma activity. Circulation, 2004; 109: 2054-2057
48. Clasen R, Schupp M, Foryst-Ludwig A, Sprang C, Clem-enz M, Krikov M, Thöne-Reineke C, Unger T, and Kintscher U: PPARgamma-activating angiotensin type-1 receptor blockers induce adiponectin. Hypertension, 2005; 46: 137-143
49. Yamagishi S and Takeuchi M: Telmisartan is a promising cardiometabolic sartan due to its unique PPAR-gamma-inducing property. Med Hypotheses, 2005; 64: 476-478
50. Nakaya K, Ayaori M, Hisada T, Sawada S, Tanaka N, Iwa-moto N, Ogura M, Yakushiji E, Kusuhara M, Nakamura H, and Ohsuzu F: Telmisartan enhances cholesterol efflux from THP-1 macrophages by activating PPARgamma. J Atheroscler Thromb, 2007; 14: 133-141
51. Komiya N, Hirose H, Kawabe H, Itoh H, and Saito I: Effects of telmisartan therapy on metabolic profiles and serum high molecular weight (HMW)-adiponectin level in Japanese male hypertensive subjects with abdominal obesity. J Atheroscler Thromb, 2009; 16: 137-142
52. Kawai T, Takei I, Oguma Y, Ohashi N, Tokui M, Oguchi S, Katsukawa F, Hirose H, Shimada A, Watanabe K, and Sa-ruta T: Effects of troglitazone on fat distribution in the treatment of male type 2 diabetes. Metabolism, 1999; 48: 1102-1107
53. Dormandy JA, Charbonnel B, Eckland DJ, Erdmann E, Massi-Benedetti M, Moules IK, Skene AM, Tan MH, Lefèbvre PJ, Murray GD, Standl E, Wilcox RG, Wilhelmsen L, Betteridge J, Birkeland K, Golay A, Heine RJ, Korányi L, Laakso M, Mokán M, Norkus A, Pirags V, Podar T, Scheen A, Scherbaum W, Schernthaner G, Schmitz O, Skrha J, Smith U, and Taton J; PROactive investigators: Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet, 2005; 366: 1279-1289
54. Maeda N, Takahashi M, Funahashi T, Kihara S, Nishiza-wa H, Kishida K, Nagaretani H, Matsuda M, Komuro R, Ouchi N, Kuriyama H, Hotta K, Nakamura T, Shimo-mura I, and Matsuzawa Y: PPARy ligands increase expression and plasma concentrations of adiponectin, an adipose-derived protein. Diabetes, 2001; 50: 2094-2099
55. Yang WS, Jeng CY, Wu TJ, Tanaka S, Funahashi T, Matsuzawa Y, Wang JP, Chen CL, Tai TY, and Chuang LM: Synthetic peroxisome proliferator-activated receptor-gamma agonist, rosiglitazone, increases plasma levels of adiponectin in type 2 diabetic patients. Diabetes Care, 2002; 25: 376-380
56. Vionnet N, Hani El H, Dupont S, Gallina S, Francke S, Dotte S, De Matos F, Durand E, Leprêtre F, Lecoeur C, Gallina P, Zekiri L, Dina C, and Froguel P: Genomewide search for type 2 diabetes-susceptibility genes in French whites: evidence for a novel susceptibility locus for early-onset diabetes on chromosome 3q27-qter and independent replication of a type 2-diabetes locus on chromosome 1q21-q24. Am J Hum Genet, 2000; 67: 1470-1480
57. Kissebah AH, Sonnenberg GE, Myklebust J, Goldstein M, Broman K, James RG, Marks JA, Krakower GR, Jacob HJ, Weber J, Martin L, Blangero J, and Comuzzie AG: Quantitative trait loci on chromosomes 3 and 17 influence phenotypes of the metabolic syndrome. Proc Natl Acad Sci USA, 2000; 97: 14478-14483
58. Hara K, Boutin P, Mori Y, Tobe K, Dina C, Yasuda K, Yamauchi T, Otabe S, Okada T, Eto K, Kadowaki H, Hagura R, Akanuma Y, Yazaki Y, Nagai R, Taniyama M, Matsubara K, Yoda M, Nakano Y, Tomita M, Kimura S, Ito C, Froguel P, and Kadowaki T: Genetic variation in the gene encoding adiponectin is associated with an increased risk of type 2 diabetes in the Japanese population. Diabetes, 2002; 51: 536-540
59. Kondo H, Shimomura I, Matsukawa Y, Kumada M, Taka-hashi M, Matsuda M, Ouchi N, Kihara S, Kawamoto T, Sumitsuji S, Funahashi T, and Matsuzawa Y: Association of adiponectin mutation with type 2 diabetes: a candidate gene for the insulin resistance syndrome. Diabetes, 2002; 51: 2325-2328
60. Deeb SS, Fajas L, Nemoto M, Pihlajamäki J, Mykkänen L, Kuusisto J, Laakso M, Fujimoto W, and Auwerx J: A Pro12Ala substitution in PPARgamma2 associated with decreased receptor activity, lower body mass index and improved insulin sensitivity. Nat Genet, 1998; 20: 284-287